Wednesday, January 12, 2022 IND234 substudy A: A Phase II Study of Adavosertib (AZD1775), A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 was closed to accrual as of today. Although accrual is now closed to this substudy, treatment and follow up of patients will continue according to the protocol. Please note the IND.234 main study and other substudies remain open to accrual. IND223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer was closed to accrual as of today after reaching its accrual target. Although accrual is now closed to this study, follow up of patients will continue according to the protocol. Please note that IND.223 was screening under the IND.234 master protocol, and IND.234 remains open to accrual.
